aTYR PHARMA INC Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
aTYR PHARMA INC (ATYR) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $26.52 million as of 2017-03-31, per its 10-Q filed 2017-05-11.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2017-05-11
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $26.52M.
- 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $21.08M.
- 2015-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $69.33M.
- 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $53.58M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2017-03-31 | $26.52M 10-Q · filed 2017-05-11 |
| 2016-03-31 | $21.08M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $69.33M 10-K · filed 2016-03-30 |
| 2015-09-30 | $53.58M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $69.31M 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |